Atlas-backed Diagonal Therapeutics launches with $128M

The Cambridge biotech is working on new ways to discover and develop “agonist antibodies,” and its Series A round was co-led by Atlas Venture and BVF Partners.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news